These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29366406)

  • 1. Preparation of Potent Leptin Receptor Antagonists and Their Therapeutic Use in Mouse Models of Uremic Cachexia and Kidney Fibrosis.
    Mak RH; Cheung WW; Solomon G; Gertler A
    Curr Pharm Des; 2018; 24(9):1012-1018. PubMed ID: 29366406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel superactive leptin antagonists and their potential therapeutic applications.
    Gertler A; Elinav E
    Curr Pharm Des; 2014; 20(4):659-65. PubMed ID: 23688008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice.
    Cheung WW; Ding W; Gunta SS; Gu Y; Tabakman R; Klapper LN; Gertler A; Mak RH
    J Am Soc Nephrol; 2014 Jan; 25(1):119-28. PubMed ID: 24115476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting the therapeutic potential of leptin signaling in cachexia.
    Mak RH; Cheung WW; Gertler A
    Curr Opin Support Palliat Care; 2014 Dec; 8(4):352-7. PubMed ID: 25259544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Large-scale preparation and characterization of non-pegylated and pegylated superactive ovine leptin antagonist.
    Niv-Spector L; Shpilman M; Boisclair Y; Gertler A
    Protein Expr Purif; 2012 Feb; 81(2):186-92. PubMed ID: 22040607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of high affinity leptins and leptin antagonists.
    Shpilman M; Niv-Spector L; Katz M; Varol C; Solomon G; Ayalon-Soffer M; Boder E; Halpern Z; Elinav E; Gertler A
    J Biol Chem; 2011 Feb; 286(6):4429-42. PubMed ID: 21119198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Leptin Receptor Antagonist Attenuates Adipose Tissue Browning and Muscle Wasting in Infantile Nephropathic Cystinosis-Associated Cachexia.
    Gonzalez A; Cheung WW; Perens EA; Oliveira EA; Gertler A; Mak RH
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin and inflammation-associated cachexia in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Kidney Int; 2006 Mar; 69(5):794-7. PubMed ID: 16518340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale preparation of biologically active mouse and rat leptins and their L39A/D40A/F41A muteins which act as potent antagonists.
    Salomon G; Niv-Spector L; Gussakovsky EE; Gertler A
    Protein Expr Purif; 2006 May; 47(1):128-36. PubMed ID: 16289983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment.
    Chen L; Yang T; Lu DW; Zhao H; Feng YL; Chen H; Chen DQ; Vaziri ND; Zhao YY
    Biomed Pharmacother; 2018 May; 101():670-681. PubMed ID: 29518614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin as an uremic toxin: Deleterious role of leptin in chronic kidney disease.
    Alix PM; Guebre-Egziabher F; Soulage CO
    Biochimie; 2014 Oct; 105():12-21. PubMed ID: 25010649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease.
    Mak RH; Cheung W; Cone RD; Marks DL
    Pediatr Nephrol; 2005 Mar; 20(3):427-31. PubMed ID: 15662537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated Human Leptin D23L Mutant-Preparation and Biological Activity In Vitro and In Vivo in Male ob/ob Mice.
    Gertler A; Solomon G
    Endocrinology; 2019 Apr; 160(4):891-898. PubMed ID: 30802285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiopoietin-like protein 2 increases renal fibrosis by accelerating transforming growth factor-β signaling in chronic kidney disease.
    Morinaga J; Kadomatsu T; Miyata K; Endo M; Terada K; Tian Z; Sugizaki T; Tanigawa H; Zhao J; Zhu S; Sato M; Araki K; Iyama K; Tomita K; Mukoyama M; Tomita K; Kitamura K; Oike Y
    Kidney Int; 2016 Feb; 89(2):327-41. PubMed ID: 26806834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia.
    Lin CY; Hsu YJ; Hsu SC; Chen Y; Lee HS; Lin SH; Huang SM; Tsai CS; Shih CC
    J Mol Cell Cardiol; 2015 Aug; 85():249-61. PubMed ID: 26093151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin is a coactivator of TGF-beta in unilateral ureteral obstructive kidney disease.
    Kümpers P; Gueler F; Rong S; Mengel M; Tossidou I; Peters I; Haller H; Schiffer M
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1355-62. PubMed ID: 17686962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tanshinone IIA attenuates renal fibrosis and inflammation via altering expression of TGF-β/Smad and NF-κB signaling pathway in 5/6 nephrectomized rats.
    Wang DT; Huang RH; Cheng X; Zhang ZH; Yang YJ; Lin X
    Int Immunopharmacol; 2015 May; 26(1):4-12. PubMed ID: 25744602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation of leptin antagonists by site-directed mutagenesis of human, ovine, rat, and mouse leptin's site III: implications on blocking undesired leptin action in vivo.
    Solomon G; Niv-Spector L; Gonen-Berger D; Callebaut I; Djiane J; Gertler A
    Ann N Y Acad Sci; 2006 Dec; 1091():531-9. PubMed ID: 17341642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated leptin antagonist with strong orexigenic activity in mice is not effective in chickens.
    Gertler A; Shinder D; Yosefi S; Shpilman M; Rosenblum CI; Ruzal M; Seroussi E; Friedman-Einat M
    J Exp Biol; 2014 Jan; 217(Pt 2):180-4. PubMed ID: 24115063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor counteracts transforming growth factor-beta1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.
    Inoue T; Okada H; Kobayashi T; Watanabe Y; Kanno Y; Kopp JB; Nishida T; Takigawa M; Ueno M; Nakamura T; Suzuki H
    FASEB J; 2003 Feb; 17(2):268-70. PubMed ID: 12475893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.